Page 110 - JCBP-3-3

Journal of Clinical and
Basic Psychosomatics Comorbid MDD and FMS

are effective in treating FMS and MDD, which may be Writing – original draft: Junjun Liu
attributed to their dual action on pain pathways and mood Writing – review & editing: Junjun Liu, Zuonian Zhang
regulation. The addition of pregabalin, which modulates
6
calcium channels and reduces neurotransmitter release, Ethics approval and consent to participate
further targets the pain component of FMS. 8 Written informed consent was obtained from the subject.
This case emphasizes the importance of a
multidisciplinary approach in managing comorbid Consent for publication
FMS and MDD. The integration of pharmacotherapy, Written informed consent was obtained from the patient for
psychotherapy, and lifestyle modification addresses the the publication of this case report and any accompanying
multifaceted nature of these conditions and provides a images. All personal identifying information has been
more comprehensive treatment strategy. The patient’s removed or masked to protect patient privacy. The patient
8
sustained improvement over a 3-month period illustrates has explicitly approved the use of their clinical data for
the potential for effective long-term management of academic publication purposes, and a signed consent form
comorbid FMS and MDD with appropriate treatment is available on request.
and ongoing care. However, treatment responses can
vary among individuals, and personalized approaches are Availability of data
necessary to achieve optimal outcomes. Not applicable.
Because this is a single case report with limited statistical
power, generalizing the findings to a broader population References
is challenging. Therefore, future multicenter studies with 1. Clauw DJ. Fibromyalgia: A clinical review. JAMA.
larger sample sizes are required to confirm and validate our 2014;311(15):1547-1555.
findings. doi: 10.1001/jama.2014.3266
4. Conclusion 2. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American
College of Rheumatology preliminary diagnostic criteria
This case report highlights the intricate relationship for fibromyalgia and measurement of symptom severity.
between FMS and MDD, emphasizing the need for Arthritis Care Res (Hoboken). 2010;62(5):600-610.
clinicians to consider both conditions when evaluating doi: 10.1002/acr.20140
patients with chronic pain and mood symptoms.
Understanding the shared pathophysiological 3. Gracely RH, Ceko M, Bushnell MC. Fibromyalgia and
mechanisms can inform more targeted and effective depression. Pain Res Treat. 2012;2012:486590.
treatment strategies. Future studies should focus on doi: 10.1155/2012/486590
elucidating the precise neurobiological underpinnings 4. Fietta P, Fietta P, Manganelli P. Fibromyalgia and psychiatric
of this comorbidity and developing novel therapeutic disorders. Acta Biomed. 2007;78(2):88-95.
approaches that address both the pain and affective 5. Maletic V, Raison CL. Neurobiology of depression,
components of these disorders. fibromyalgia and neuropathic pain. Front Biosci (Landmark
Ed). 2009;14(14):5291-5338.
Acknowledgments
doi: 10.2741/3598
None.
6. Häuser W, Ablin J, Fitzcharles MA, et al. Fibromyalgia. Nat
Funding Rev Dis Primers. 2015;1:15022.

None. doi: 10.1038/nrdp.2015.22
7. Aguglia A, Salvi V, Maina G, Rossetto I, Aguglia E.
Conflict of interest Fibromyalgia syndrome and depressive symptoms:
Comorbidity and clinical correlates. J Affect Disord.
The authors declare that they have no competing interests.
2011;128(3):262-266.
Author contributions doi: 10.1016/j.jad.2010.07.004
Conceptualization: Junjun Liu 8. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised
Formal analysis: Lihua Zhang recommendations for the management of fibromyalgia. Ann
Investigation: Junjun Liu, Yang liu, Zhaomin Lu Rheum Dis. 2017;76(2):318-328.
Methodology: Zhiye Wang, Mengyuan Ni doi: 10.1136/annrheumdis-2016-209724

Volume 3 Issue 3 (2025) 104 doi: 10.36922/jcbp.5069